Journal of Neuro-Oncology

, Volume 65, Issue 1, pp 63–75

Targeting the Over-Expressed Urokinase-Type Plasminogen Activator Receptor on Glioblastoma Multiforme

  • Edward Rustamzadeh
  • Chunbin Li
  • Sekou Doumbia
  • Walter A. Hall
  • Daniel A. Vallera
Article

DOI: 10.1023/A:1026238331739

Cite this article as:
Rustamzadeh, E., Li, C., Doumbia, S. et al. J Neurooncol (2003) 65: 63. doi:10.1023/A:1026238331739

Abstract

A recombinant fusion protein targeting the urokinase-type plasminogen activator receptor (uPAR) and delivering a potent catalytic toxin has the advantage of simultaneously targeting both over-expressed uPAR on glioblastoma cells and on the tumor neovasculature. Such a hybrid protein was synthesized consisting of the noninternalizing amino-terminal fragment (ATF) of urokinase-type plasminogen activator (uPA) for binding, and the catalytic portion of diphtheria toxin (DT) for killing, and the translocation enhancing region (TER) of DT for internalization. The protein was highly selective for human glioblastoma in vitro and in vivo. In vivo, this DT/ATF hybrid called DTAT caused the regression of small subcutaneous uPAR-expressing tumors with minimal toxicity to critical organs. In vitro, DTAT killed only uPAR-positive glioblastoma cell lines and human endothelial cells in the form of the HUVEC cell line. Killing was selective and blockable with specific antibody. DTAT was highly effective against tumor cells cultured from glioblastoma multiforme patients and in vitro mixing experiments combining DTAT with DTIL13 another highly effective anti-glioblastoma agent showed that the mixture was as toxic as the most potent immunotoxin. In this article, we review our progress to date with DTAT.

diphtheria toxin glioblastoma immunotoxin nude mice urokinase 

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Edward Rustamzadeh
    • 1
  • Chunbin Li
    • 2
  • Sekou Doumbia
    • 3
  • Walter A. Hall
    • 1
  • Daniel A. Vallera
    • 2
  1. 1.Department of NeurosurgeryUniversity of Minnesota Cancer CenterMinneapolisUSA
  2. 2.Department of Therapeutic Radiology-Radiation OncologySection on Molecular Cancer TherapeuticsMinneapolisUSA
  3. 3.R&D Systems, Inc.MinneapolisUSA